Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1954 1
1955 1
1960 1
1961 1
1963 2
1964 1
1965 1
1986 2
1987 1
1988 1
1989 2
1990 3
1991 6
1992 3
1993 10
1994 9
1995 10
1996 11
1997 11
1998 24
1999 20
2000 25
2001 29
2002 47
2003 54
2004 75
2005 84
2006 95
2007 111
2008 123
2009 124
2010 148
2011 105
2012 130
2013 115
2014 117
2015 115
2016 108
2017 102
2018 101
2019 101
2020 105
2021 97
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

1,986 results
Results by year
Filters applied: . Clear all
Page 1
Precision Medicine for Idiopathic Hypersomnia.
Arnulf I, Leu-Semenescu S, Dodet P. Arnulf I, et al. Sleep Med Clin. 2019 Sep;14(3):333-350. doi: 10.1016/j.jsmc.2019.05.007. Sleep Med Clin. 2019. PMID: 31375202 Review.
In some IH cases, an endogenous hypnotic peptide stimulating GABA receptors during wakefulness is suspected, which are improved by anti-GABA drugs. The benefits of modafinil, sodium oxybate, mazindol, and pitolisant were found in mostly retrospective studies....
In some IH cases, an endogenous hypnotic peptide stimulating GABA receptors during wakefulness is suspected, which are improved by anti-GABA …
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Nourbakhsh B, et al. Lancet Neurol. 2021 Jan;20(1):38-48. doi: 10.1016/S1474-4422(20)30354-9. Epub 2020 Nov 23. Lancet Neurol. 2021. PMID: 33242419 Free PMC article. Clinical Trial.
FINDINGS: Between Oct 4, 2017, and Feb 27, 2019, of 169 patients screened, 141 patients were enrolled and randomly assigned to one of four medication administration sequences: 35 (25%) patients to the amantadine, placebo, modafinil, and methylphenidate sequence; 34 (24%) p …
FINDINGS: Between Oct 4, 2017, and Feb 27, 2019, of 169 patients screened, 141 patients were enrolled and randomly assigned to one of four m …
Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.
Gibbons C, Pagnini F, Friede T, Young CA. Gibbons C, et al. Cochrane Database Syst Rev. 2018 Jan 2;1(1):CD011005. doi: 10.1002/14651858.CD011005.pub2. Cochrane Database Syst Rev. 2018. PMID: 29293261 Free PMC article. Review.
DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. MAIN RESULTS: We included one pharmacological (modafinil) study and three non-pharmacological studies (resistance exercise, respiratory exercise, and repetitive transcranial …
DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. MAIN RESULTS: We included one pharmacolog …
Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review.
Battleday RM, Brem AK. Battleday RM, et al. Eur Neuropsychopharmacol. 2015 Nov;25(11):1865-81. doi: 10.1016/j.euroneuro.2015.07.028. Epub 2015 Aug 20. Eur Neuropsychopharmacol. 2015. PMID: 26381811 Review.
In addition to its approved use treating excessive somnolence, modafinil is thought to be used widely off-prescription for cognitive enhancement. ...In order to provide an up-to-date systematic evaluation that addresses these concerns, we searched MEDLINE with the terms " …
In addition to its approved use treating excessive somnolence, modafinil is thought to be used widely off-prescription for cognitive …
The holistic management of fatigue within palliative care.
Dean A. Dean A. Int J Palliat Nurs. 2019 Aug 2;25(8):368-376. doi: 10.12968/ijpn.2019.25.8.368. Int J Palliat Nurs. 2019. PMID: 31437105 Review.
FINDINGS: Research appears to support different interventions at various points in the disease trajectory and this is of importance for service design as palliative care is increasingly introduced earlier in the patient's pathway. CONCLUSION: Although the body of research …
FINDINGS: Research appears to support different interventions at various points in the disease trajectory and this is of importance for serv …
[Doping for the brain].
Iglseder B. Iglseder B. Z Gerontol Geriatr. 2018 Feb;51(2):143-148. doi: 10.1007/s00391-017-1351-y. Epub 2017 Dec 5. Z Gerontol Geriatr. 2018. PMID: 29209802 Review. German.
Brain doping, however, specifies the use of illegal substances or prescription drugs beyond approval with the purpose of cognitive enhancement. Only amphetamines, methylphenidate and modafinil have significant effects on attentiveness, concentration and alertness, whereas …
Brain doping, however, specifies the use of illegal substances or prescription drugs beyond approval with the purpose of cognitive enhanceme …
Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review.
Gagnon DJ, Leclerc AM, Riker RR, Brown CS, May T, Nocella K, Cote J, Eldridge A, Seder DB. Gagnon DJ, et al. Neurocrit Care. 2020 Aug;33(1):283-297. doi: 10.1007/s12028-020-00977-5. Neurocrit Care. 2020. PMID: 32394130
Modafinil was initiated 170 (17, 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350) mg/day, respectively. ...A positive response in at least one clinical effectiveness measure was reported in 70% of amantadine publications
Modafinil was initiated 170 (17, 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350
Pharmacologic Management of Excessive Daytime Sleepiness.
Takenoshita S, Nishino S. Takenoshita S, et al. Sleep Med Clin. 2020 Jun;15(2):177-194. doi: 10.1016/j.jsmc.2020.02.006. Sleep Med Clin. 2020. PMID: 32386693 Review.
EDS is usually treated using amphetamine-like central nervous system stimulants or modafinil and its R-enantiomer, armodafinil, wake-promoting compounds unrelated to amphetamines; a variety of new drugs are under development. ...
EDS is usually treated using amphetamine-like central nervous system stimulants or modafinil and its R-enantiomer, armodafinil, wake- …
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, Hsieh SC, Bai Z, Hossain A, Skidmore B, Tsakonas E, Chojecki D, Mamdani M, Wells GA. Elliott J, et al. PLoS One. 2020 Oct 21;15(10):e0240584. doi: 10.1371/journal.pone.0240584. eCollection 2020. PLoS One. 2020. PMID: 33085721 Free PMC article.
Data were pooled via pair-wise meta-analyses and Bayesian network meta-analyses. Risk of bias was assessed by use of Cochrane's Risk of Bias tool, and the certainty of the evidence was assessed by use of the GRADE framework. ...Included pharmacotherapies were methylphenida …
Data were pooled via pair-wise meta-analyses and Bayesian network meta-analyses. Risk of bias was assessed by use of Cochrane's Risk …
Modafinil: a review of neurochemical actions and effects on cognition.
Minzenberg MJ, Carter CS. Minzenberg MJ, et al. Neuropsychopharmacology. 2008 Jun;33(7):1477-502. doi: 10.1038/sj.npp.1301534. Epub 2007 Aug 22. Neuropsychopharmacology. 2008. PMID: 17712350 Review.
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. ...We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibit
Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. ...We add
1,986 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page